Zotizalkib, gilteritinib, and neladalkib might represent promising alternatives to lorlatinib as second-line treatments for ALK-positive NSCLC.<h4>Key points</h4>• A PCR-based mutation prediction system was successfully applied to fourth-generation ALK inhibitors. The gene discussed is ALK; the disease is non-small cell lung carcinoma.